These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 9002976)
21. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Gianni AM; Magni M; Martelli M; Di Nicola M; Carlo-Stella C; Pilotti S; Rambaldi A; Cortelazzo S; Patti C; Parvis G; Benedetti F; Capria S; Corradini P; Tarella C; Barbui T Blood; 2003 Jul; 102(2):749-55. PubMed ID: 12663455 [TBL] [Abstract][Full Text] [Related]
22. Polymerase chain reaction detection of cells carrying t(14;18) in bone marrow of patients with follicular and diffuse large B-cell lymphoma: the importance of analysis at diagnosis and significance of long-term follow-up. Papajík T; Jedlicková K; Kriegová E; Jarosová M; Raida L; Faber E; Hubácek J; Vondráková J; Pikalová Z; Indrák K Neoplasma; 2001; 48(6):501-5. PubMed ID: 11949845 [TBL] [Abstract][Full Text] [Related]
23. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. Gribben JG; Freedman As; Woo SD; Blake K; Shu RS; Freeman G; Longtine JA; Pinkus GS; Nadler LM Blood; 1991 Dec; 78(12):3275-80. PubMed ID: 1742487 [TBL] [Abstract][Full Text] [Related]
24. High degree of occult tumor contamination in bone marrow and peripheral blood stem cells of patients undergoing autologous transplantation for non-Hodgkin's lymphoma. McCann JC; Kanteti R; Shilepsky B; Miller KB; Sweet M; Schenkein DP Biol Blood Marrow Transplant; 1996 Feb; 2(1):37-43. PubMed ID: 9078353 [TBL] [Abstract][Full Text] [Related]
25. Real-time polymerase chain reaction in multiple myeloma: quantitative analysis of tumor contamination of stem cell harvests. Ladetto M; Omedè P; Sametti S; Donovan JW; Astolfi M; Drandi D; Volpato F; Giaccone L; Giaretta F; Palumbo A; Bruno B; Pileri A; Gribben JG; Boccadoro M Exp Hematol; 2002 Jun; 30(6):529-36. PubMed ID: 12063019 [TBL] [Abstract][Full Text] [Related]
26. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Magni M; Di Nicola M; Devizzi L; Matteucci P; Lombardi F; Gandola L; Ravagnani F; Giardini R; Dastoli G; Tarella C; Pileri A; Bonadonna G; Gianni AM Blood; 2000 Aug; 96(3):864-9. PubMed ID: 10910898 [TBL] [Abstract][Full Text] [Related]
27. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Pott C; Hoster E; Delfau-Larue MH; Beldjord K; Böttcher S; Asnafi V; Plonquet A; Siebert R; Callet-Bauchu E; Andersen N; van Dongen JJ; Klapper W; Berger F; Ribrag V; van Hoof AL; Trneny M; Walewski J; Dreger P; Unterhalt M; Hiddemann W; Kneba M; Kluin-Nelemans HC; Hermine O; Macintyre E; Dreyling M Blood; 2010 Apr; 115(16):3215-23. PubMed ID: 20032498 [TBL] [Abstract][Full Text] [Related]
28. High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Freedman AS; Gribben JG; Neuberg D; Mauch P; Soiffer RJ; Anderson KC; Pandite L; Robertson MJ; Kroon M; Ritz J; Nadler LM Blood; 1996 Oct; 88(7):2780-6. PubMed ID: 8839876 [TBL] [Abstract][Full Text] [Related]
29. High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilization. Tarella C; Di Nicola M; Caracciolo D; Zallio F; Cuttica A; Omedè P; Bondesan P; Magni M; Matteucci P; Gallamini A; Pileri A; Gianni AM Bone Marrow Transplant; 2002 Dec; 30(11):725-32. PubMed ID: 12439694 [TBL] [Abstract][Full Text] [Related]
30. [Contamination with minimal residual disease in autologous peripheral stem cell collected from Non-Hodgkin's lymphoma patients treated with high-dose therapy]. Zhou A; Shi Y; Feng F; Lu S; He X; Han X Zhonghua Zhong Liu Za Zhi; 2002 Sep; 24(5):467-70. PubMed ID: 12485501 [TBL] [Abstract][Full Text] [Related]
31. Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years. Kolstad A; Pedersen LB; Eskelund CW; Husby S; Grønbæk K; Jerkeman M; Laurell A; Räty R; Elonen E; Andersen NS; Brown PD; Kimby E; Bentzen H; Sundström C; Ehinger M; Karjalainen-Lindsberg ML; Delabie J; Ralfkiær E; Fagerli UM; Nilsson-Ehle H; Lauritzsen GF; Kuittinen O; Niemann C; Geisler CH; Biol Blood Marrow Transplant; 2017 Mar; 23(3):428-435. PubMed ID: 28039078 [TBL] [Abstract][Full Text] [Related]
32. High-dose cyclophosphamide followed by autologous peripheral blood progenitor cell transplantation improves the salvage treatment for persistent or sensitive relapsed malignant lymphoma. Baldissera RC; Aranha JF; Oliveira GB; Vigorito AC; Eid KA; Miranda EC; De Souza CA Braz J Med Biol Res; 2002 Jan; 35(1):49-57. PubMed ID: 11743614 [TBL] [Abstract][Full Text] [Related]
33. High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting. Corradini P; Voena C; Astolfi M; Ladetto M; Tarella C; Boccadoro M; Pileri A Blood; 1995 Mar; 85(6):1596-602. PubMed ID: 7888677 [TBL] [Abstract][Full Text] [Related]
34. Detection of minimal residual disease in hematopoietic progenitor cell harvests: lack of predictive value of peripheral blood and bone marrow analysis in mantle cell and indolent lymphoma. Magni M; Di Nicola M; Carlo-Stella C; Matteucci P; Devizzi L; Guidetti A; Ravagnani F; Gianni AM Am J Blood Res; 2012; 2(2):105-12. PubMed ID: 22762029 [TBL] [Abstract][Full Text] [Related]
35. Autologous stem cell transplantation (ASCT) with immunologically purged progenitor cells in patients with advanced stage follicular lymphoma after early partial or complete remission: toxicity, follow-up of minimal residual disease and survival. González-Barca E; Fernández de Sevilla A; Domingo-Claros A; Romagosa V; Martín-Henao GA; De Sanjose S; Carmona M; Petit J; García J; Grañena A Bone Marrow Transplant; 2000 Nov; 26(10):1051-6. PubMed ID: 11108302 [TBL] [Abstract][Full Text] [Related]
37. Peripheral blood progenitor cell transplantation in lymphoma and leukemia using a single apheresis. Pettengell R; Morgenstern GR; Woll PJ; Chang J; Rowlands M; Young R; Radford JA; Scarffe JH; Testa NG; Crowther D Blood; 1993 Dec; 82(12):3770-7. PubMed ID: 7505124 [TBL] [Abstract][Full Text] [Related]
38. Outcome of high-dose therapy and autologous transplantation in non-Hodgkin's lymphoma based on the presence of tumor in the marrow or infused hematopoietic harvest. Sharp JG; Kessinger A; Mann S; Crouse DA; Armitage JO; Bierman P; Weisenburger DD J Clin Oncol; 1996 Jan; 14(1):214-9. PubMed ID: 8558200 [TBL] [Abstract][Full Text] [Related]
39. Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin's lymphoma. Micallef IN; Apostolidis J; Rohatiner AZ; Wiggins C; Crawley CR; Foran JM; Leonhardt M; Bradburn M; Okukenu E; Salam A; Matthews J; Cavenagh JD; Gupta RK; Lister TA Hematol J; 2000; 1(6):367-73. PubMed ID: 11920216 [TBL] [Abstract][Full Text] [Related]
40. Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: a GOELAMS phase II study. Colombat P; Cornillet P; Deconinck E; Tourani JM; Gardembas M; Delain M; Abgrall JF; Kootz C; Milpied N Bone Marrow Transplant; 2000 Nov; 26(9):971-7. PubMed ID: 11100276 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]